Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP | Zendy

Muzamil Jawed | Zendy; Amna Khalid | Zendy; Mayer Rubin | Zendy; Ramsha Shafiq | Zendy; Nail Cemalovic | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP

Author(s) -

Muzamil Jawed,

Amna Khalid,

Mayer Rubin,

Ramsha Shafiq,

Nail Cemalovic

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab343

Subject(s) - medicine , immunology , vaccination , immune thrombocytopenia , cytomegalovirus , immune system , virus , coronavirus , autoimmunity , virology , covid-19 , viral disease , disease , antibody , infectious disease (medical specialty) , herpesviridae

Immune thrombocytopenia (ITP) is an autoimmune condition associated with multiple risk factors including viral infections (hepatitis B virus/hepatitis C virus/cytomegalovirus, HIV, and recently severe acute respiratory syndrome coronavirus 2) and vaccines. Though immune mechanisms have been proposed to explain the pathogenesis of acute ITP, autoimmunity with the coronavirus disease 2019 (COVID-19) vaccine is still unclear and needs further research. We report a case of acute ITP after administration of the Pfizer-BioNTech mRNA COVID-19 vaccine in a patient with previously stable ITP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research